Weekly Policy Blog: August Prescription Drug Affordability Review Board (PDAB) Meeting
By: Colorado BioScience Association Date: 09/02/2022
On August 26, CBSA and our partners participated in the state Prescription Drug Affordability Review Board (PDAB) meeting, which was open to the public. The PDAB was created in 2021 when the state leg...
Learn MoreWeekly Policy Blog: Ethylene Oxide – Critical in Protecting Patient Health
By: Colorado BioScience Association Date: 08/26/2022
Ethylene Oxide (EtO or EO) is a colorless gas used commercially in a wide variety of ways, including the production of textiles, personal care items, and the sterilization of medical devices, cosmetic...
Learn MoreWeekly Policy Blog: President Biden Signs Inflation Reduction Act into Law
By: Colorado BioScience Association Date: 08/17/2022
On August 16, 2022, President Biden signed the Inflation Reduction Act, a bill aimed at addressing high inflationary costs. The massive bill increases corporate taxes and includes measures designed to...
Learn MoreWeekly Policy Blog: Deadline Approaches to Reauthorize User Fee Agreements
By: Colorado BioScience Association Date: 08/12/2022
CBSA and our national partners support the renewal of the critically important User Fee Agreements, including the Pharmaceutical Drug User Fee Act (PDUFA) and the Medical Device User Fee Act (MDUFA)....
Learn MoreCBSA Remains Active on Critical Federal Legislation
By: Colorado BioScience Association Date: 08/05/2022
Act Today and Tell Your Member of Congress: Oppose Government Price Setting Congress is negotiating sweeping legislation that impacts life sciences. The current reconciliation bill includes language t...
Learn MoreWeekly Policy Blog: CBSA’s Continued Advocacy on Important Federal Policy Initiatives
By: Colorado BioScience Association Date: 07/29/2022
Congress is negotiating sweeping legislation that impacts life sciences. Colorado BioScience Association (CBSA) remains active on these important legislative proposals, which include supporting the re...
Learn MoreWeekly Policy Update: SBIR/STTR Critical to Life Sciences – Support Our Work on Reauthorization
By: Colorado BioScience Association Date: 07/22/2022
The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs are vital for our life sciences community. They provide early non-dilutive funding to advance high-...
Learn MoreWeekly Policy Update: Senate Prescription Drug Pricing Legislation
By: Colorado BioScience Association Date: 07/15/2022
Democrats in the U.S. Senate continue to negotiate an economic package that advances President Joe Biden’s key priorities. Prescription drug pricing legislation that would drastically alter the Medica...
Learn MoreWeekly Policy Update: Where We Stand Today on Reauthorization of SBIR/STTR
By: Colorado BioScience Association Date: 07/08/2022
The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs are vital for our life sciences community. They provide early non-dilutive funding to help advance...
Learn MoreWeekly Policy Update: CBSA Urges Repeal of Harmful R&D Amortization Provision
By: Colorado BioScience Association Date: 07/01/2022
Earlier this month, Colorado BioScience Association (CBSA) partnered with Biotechnology Innovation Organization (BIO) and sent a letter to Congress urging immediate legislative action to repeal the ha...
Learn More